NYSE:PRGOPerrigo Stock Price, Forecast & News

Perrigo's stock was trading at $46.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRGO stock has decreased by 3.6% and is now trading at $44.36. View which stocks have been mosted impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Perrigo.

Perrigo is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Perrigo.

Perrigo Company PLC (NYSE:PRGO) issued its quarterly earnings results on Thursday, February, 27th. The company reported $1.06 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.09 by $0.03. The firm earned $1.32 billion during the quarter, compared to the consensus estimate of $1.31 billion. Perrigo had a net margin of 3.02% and a return on equity of 9.56%. Perrigo's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.97 EPS. View Perrigo's earnings history.

Perrigo declared a quarterly dividend on Tuesday, February 18th. Shareholders of record on Friday, February 28th will be paid a dividend of $0.225 per share on Tuesday, March 17th. This represents a $0.90 dividend on an annualized basis and a dividend yield of 2.03%. The ex-dividend date of this dividend is Thursday, February 27th. This is a positive change from Perrigo's previous quarterly dividend of $0.21. View Perrigo's dividend history.

Perrigo issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 27th. The company provided EPS guidance of 3.95-4.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.37. The company issued revenue guidance of $5.128-5.176 billion, compared to the consensus revenue estimate of $5.02 billion.

8 Wall Street analysts have issued 12 month price objectives for Perrigo's stock. Their forecasts range from $52.00 to $70.00. On average, they anticipate Perrigo's share price to reach $56.86 in the next year. This suggests a possible upside of 28.2% from the stock's current price. View analysts' price targets for Perrigo.

News coverage about PRGO stock has trended very negative on Saturday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Perrigo earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutPerrigo.

Perrigo saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 5,269,200 shares, an increase of 11.2% from the February 27th total of 4,740,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the days-to-cover ratio is presently 4.7 days. Approximately 3.9% of the company's shares are sold short. View Perrigo's Current Options Chain.

Some companies that are related to Perrigo include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Perrigo investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Mylan (MYL), Allergan (AGN), Celgene (CELG), Netflix (NFLX), AbbVie (ABBV), Amgen (AMGN), Starbucks (SBUX) and Johnson & Johnson (JNJ).

Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRGO stock can currently be purchased for approximately $44.36.

Perrigo has a market capitalization of $6.04 billion and generates $4.84 billion in revenue each year. The company earns $146.10 million in net income (profit) each year or $4.03 on an earnings per share basis. Perrigo employs 11,200 workers across the globe. View additional information about Perrigo.

The official website for Perrigo is http://www.perrigo.com/.

Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]